A, low risk of bias：the study met almost criteria; B, moderate risk of
bias ：the study met part or unclear for one or more quality criteria;
C, high risk of bias ：the study was not met or included
criteria；†ANOVA：analysis of
variance；‡ITT：Intention-to-treat；§NA：
not available；
Figure 1 . PRISMA flow diagram demonstrating the progress of
study evaluation throughout the review.
Figure 2 . Forest plots of
(A)：the relationship between patient with asthma or allergic rhinitis
use montelukast and the occurrence of neuropsychiatric events and (B):
funnel plot of the included studies.
Figure 3 . Forest plots of patients with asthma or rhinitis have
been linked to a neuropsychiatric event called headache
Figure 4 . Forest plots of (A):the relationship between the use
of montelukast and neuropsychiatric events in asthma patients
and（B）the relationship between the use of montelukast and
neuropsychiatric events in patients with rhinitis.
Figure 5 . Forest plots of (A)：the relationship between
montelukast and neuropsychiatric events in adult patients with asthma or
rhinitis and (B): the relationship between montelukast and
neuropsychiatric events in children patients with asthma or rhinitis.
Figure 6 . Funnel plot of(A):the included studies based on the
patient with montelukast or common clinical drugs analysis and forest
plots of (B)：the neuropsychiatric events between montelukast and
budesonide versus budesonide alone in asthmatic patients and (C): the
occurrence of neuropsychiatric events in patients with allergic rhinitis
compared with montelukast combined with loratadine versus loratadine
alone